{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:01:32Z","timestamp":1790056892977,"version":"4.0.1"},"reference-count":407,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DP2TR002776"],"award-info":[{"award-number":["DP2TR002776"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["129784-IRG-16-188-38-IRG"],"award-info":[{"award-number":["129784-IRG-16-188-38-IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jconrel.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T12:29:22Z","timestamp":1539088162000},"page":"256-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":186,"special_numbering":"C","title":["Biomaterials for vaccine-based cancer immunotherapy"],"prefix":"10.1016","volume":"292","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-2244","authenticated-orcid":false,"given":"Michael J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.10.008_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2014.05.011","article-title":"Combatting infectious diseases; nanotechnology as a platform for rational vaccine design","volume":"74","author":"van Riet","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/icb.2010.152","article-title":"From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease","volume":"89","author":"Mortellaro","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0020","first-page":"2665","article-title":"Failure of cancer vaccines: the significant limitations of this approach to immunotherapy","volume":"20","author":"Bodey","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.addr.2012.07.016","article-title":"Devices for overcoming biological barriers: the use of physical forces to disrupt the barriers","volume":"65","author":"Mitragotri","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0030","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.vaccine.2016.05.073","article-title":"Personalized cancer vaccines: Targeting the cancer mutanome","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0045","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.coi.2014.01.005","article-title":"Dendritic cells and cancer immunotherapy","volume":"27","author":"Radford","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.celrep.2012.01.005","article-title":"VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics","volume":"1","author":"Lund","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nature02238","article-title":"T-cell priming by dendriticcells in lymph nodes occurs in three distinct phases","volume":"427","author":"Mempel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00262-012-1366-6","article-title":"Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy","volume":"62","author":"Nobuoka","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0070","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1002\/adma.201506312","article-title":"Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody","volume":"28","author":"Wang","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0075","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"28","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.08.009","article-title":"Lymph node targeting strategies to improve vaccination efficacy","volume":"267","author":"Jiang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1208\/s12248-014-9708-2","article-title":"Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance","volume":"17","author":"Andorko","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.copbio.2016.02.001","article-title":"Biomaterials for enhancing anti-cancer immunity","volume":"40","author":"Koshy","year":"2016","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.nantod.2015.06.007","article-title":"Engineered materials for cancer immunotherapy","volume":"10","author":"Cheung","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12026-014-8537-9","article-title":"Applying biodegradable particles to enhance cancer vaccine efficacy","volume":"59","author":"Ahmed","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0105","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/2326-6066.CIR-15-0112","article-title":"Engineering new approaches to cancer vaccines","volume":"3","author":"Mehta","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0110","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1021\/acs.bioconjchem.8b00079","article-title":"Cross-linked peptide nanoclusters for delivery of oncofetal antigen as a cancer vaccine","volume":"29","author":"Tsoras","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/adhm.201501062","article-title":"Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy","volume":"5","author":"Purwada","year":"2016","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.actbio.2017.01.005","article-title":"The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response","volume":"50","author":"Wafa","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-14-0019-T","article-title":"Enhancing efficacy of anti-cancer vaccines by targeted delivery to tumor-draining lymph nodes","volume":"2","author":"Jeanbart","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0130","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1002\/adma.201200209","article-title":"Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo","volume":"24","author":"Black","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2018.04.041","article-title":"Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy","volume":"282","author":"Kuai","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0145","doi-asserted-by":"crossref","first-page":"1604366","DOI":"10.1002\/adfm.201604366","article-title":"Localized multi-component delivery platform generates local and systemic anti-tumor immunity","volume":"27","author":"Acharya","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0150","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/1061186X.2015.1048517","article-title":"Stapled endosome disrupting alginate particles for cytosolic delivery of cations","volume":"23","author":"Acharya","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0155","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1002\/adma.201200224","article-title":"Biomimetic delivery with micro-and nanoparticles","volume":"24","author":"Balmert","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-chembioeng-060817-084055","article-title":"Biodegradable polymeric nanoparticles for therapeutic cancer treatments","volume":"9","author":"Karlsson","year":"2018","journal-title":"Ann. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2017.10.013","article-title":"Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy","volume":"14","author":"Wilson","year":"2018","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.jconrel.2018.10.008_bb0170","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1002\/wnan.1506","article-title":"Immunoengineering with biomaterials for enhanced cancer immunotherapy","volume":"10","author":"Xie","year":"2018","journal-title":"Wiley Interdisciplinary Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4110\/in.2013.13.5.177","article-title":"Nanoparticle-based vaccine delivery for cancer immunotherapy","volume":"13","author":"Park","year":"2013","journal-title":"Immune Network"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.2014.851606","article-title":"Tumor lysate-loaded biodegradable microparticles as cancer vaccines","volume":"13","author":"Joshi","year":"2014","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0185","doi-asserted-by":"crossref","first-page":"1700930","DOI":"10.1002\/adhm.201700930","article-title":"Progress toward the clinical translation of bioinspired peptide and protein assemblies","volume":"7","author":"Hainline","year":"2018","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0190","doi-asserted-by":"crossref","first-page":"12519","DOI":"10.1038\/s41598-018-31089-y","article-title":"Nanoscale peptide self-assemblies boost bcg-primed cellular immunity against Mycobacterium tuberculosis","volume":"8","author":"Chesson","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0195","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.ai.2015.12.001","article-title":"Advances in therapeutic cancer vaccines","author":"Wong","year":"2016"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tibtech.2015.07.001","article-title":"Biomimetic particles as therapeutics","volume":"33","author":"Meyer","year":"2015","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0205","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1002\/adma.201402105","article-title":"Hydrogels and scaffolds for immunomodulation","volume":"26","author":"Singh","year":"2014","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12248-012-9418-6","article-title":"Biodegradable particles as vaccine delivery systems: size matters","volume":"15","author":"Joshi","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biomaterials.2013.09.050","article-title":"Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells","volume":"35","author":"Sunshine","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0220","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2017.04.024","article-title":"Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses","volume":"256","author":"Kang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In situ formed reactive oxygen species\u2013responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0230","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1021\/acsmacrolett.7b00584","article-title":"Synthetic lift-off polymer beneath layer-by-layer films for surface-mediated drug delivery","volume":"6","author":"He","year":"2017","journal-title":"ACS Macro Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2018.02.016","article-title":"Nanoscale artificial antigen presenting cells for cancer immunotherapy","volume":"98","author":"Rhodes","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1166\/jbns.2018.1498","article-title":"Synthetic vaccine characterization and design","volume":"12","author":"Zhang","year":"2018","journal-title":"J. Bionanosci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0245","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0250","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/356152a0","article-title":"Genetic immunization is a simple method for eliciting an immune response","volume":"356","author":"Tang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0255","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm813","article-title":"Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways","volume":"9","author":"Leitner","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0265","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2796.2003.01140.x","article-title":"DNA vaccines: a review","volume":"253","author":"Liu","year":"2003","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0270","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0275","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.158.8.3635","article-title":"Contribution of CpG motifs to the immunogenicity of DNA vaccines","volume":"158","author":"Klinman","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0280","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1016\/S0264-410X(02)00238-4","article-title":"Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine","volume":"20","author":"Kojima","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0285","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/21645515.2015.1035502","article-title":"DNA vaccines, electroporation and their applications in cancer treatment","volume":"11","author":"Lee","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0290","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2016.08.005","article-title":"The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery","volume":"110","author":"Kuang","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0300","doi-asserted-by":"crossref","first-page":"1700422","DOI":"10.1002\/marc.201700422","article-title":"Salt responsive morphologies of ssdna-based triblock polyelectrolytes in semi-dilute regime: effect of volume fractions and polyelectrolyte length","volume":"38","author":"Li","year":"2017","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0305","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/gt.2017.38","article-title":"Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation","volume":"24","author":"Sun","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0310","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV\u2013CRISPR\u2013Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0315","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0320","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1517\/14712598.8.11.1645","article-title":"Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration","volume":"8","author":"Chiarella","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-2727-2_2","article-title":"Gene gun Her2\/neu DNA vaccination: evaluation of vaccine efficacy in a syngeneic Her2\/neu mouse tumor model","author":"Nguyen-Hoai","year":"2015","journal-title":"Gene Therapy Solid Cancers Methods Protocols"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0330","series-title":"Mucosal Immunology","first-page":"1307","article-title":"DNA vaccines for the induction of immune responses in mucosal tissues","author":"Raska","year":"2015"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/156652311798192815","article-title":"Novel strategies to improve DNA vaccine immunogenicity","volume":"11","author":"Coban","year":"2011","journal-title":"Curr. Gene Therapy"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pharmthera.2017.02.016","article-title":"DNA vaccines for prostate cancer","volume":"174","author":"Zahm","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0345","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0350","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2460\/ajvr.72.12.1631","article-title":"Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor","volume":"72","author":"Grosenbaugh","year":"2011","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0355","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cncr.11462","article-title":"Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma","volume":"98","author":"Tagawa","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0360","first-page":"5845","article-title":"Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma","volume":"62","author":"Timmerman","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0365","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1016\/S0264-410X(03)00275-5","article-title":"Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe","volume":"21","author":"Trimble","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0370","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1078-0432.CCR-08-1725","article-title":"A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3","volume":"15","author":"Trimble","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0375","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.05.004","article-title":"DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy","volume":"165","author":"Tiptiri-Kourpeti","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0380","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jconrel.2006.04.006","article-title":"Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles","volume":"113","author":"Kasturi","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0385","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1535370216643771","article-title":"Micro-and nanoparticulates for DNA vaccine delivery","volume":"241","author":"Farris","year":"2016","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12985-016-0599-y","article-title":"Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens","volume":"13","author":"Stachyra","year":"2016","journal-title":"Virol. J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0395","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1089\/10430349950016762","article-title":"RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization","volume":"10","author":"Zhou","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0400","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0405","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1093\/nar\/29.18.3882","article-title":"Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells","volume":"29","author":"Bettinger","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0415","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"201209367","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161193","article-title":"Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge","volume":"11","author":"Magini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0425","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0430","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0435","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0440","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0450","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0460","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0465","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0470","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0475","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0480","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1021\/acsnano.6b08447","article-title":"Structurally programmed assembly of translation initiation nanoplex for superior mRNA delivery","volume":"11","author":"Li","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0485","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1096\/fasebj.10.12.8903508","article-title":"The eIF-2alpha kinases and the control of protein synthesis","volume":"10","author":"De Haro","year":"1996","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0490","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0495","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.bmcl.2018.07.033","article-title":"Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion","volume":"28","author":"Shen","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0500","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0505","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","article-title":"Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination","volume":"125","author":"Persano","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0510","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","author":"De Beuckelaer","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0515","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0520","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0525","article-title":"Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression","volume":"201701911","author":"Yu","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0530","article-title":"Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics","volume":"201620874","author":"Dahlman","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0535","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0540","series-title":"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis","author":"ClinicalTrials.Gov","year":"2018"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0545","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0550","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0555","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0560","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0565","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0570","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","article-title":"Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA","volume":"18","author":"Ball","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0575","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0580","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0585","series-title":"Advances in Cancer Research","first-page":"421","article-title":"Therapeutic cancer vaccines: past, present, and future","author":"Guo","year":"2013"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0590","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0595","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.vaccine.2012.01.016","article-title":"Recombinant protein vaccines produced in insect cells","volume":"30","author":"Cox","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0600","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0605","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J. (Sudbury, Mass.)"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0610","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2009.01.018","article-title":"Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies","volume":"27","author":"Chianese-Bullock","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0615","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41563-018-0028-2","article-title":"A facile approach to enhance antigen response for personalized cancer vaccination","volume":"17","author":"Li","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0620","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0625","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.peptides.2009.10.002","article-title":"Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery","volume":"31","author":"Tan","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0630","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.7150\/thno.20118","article-title":"Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy","volume":"7","author":"Zhai","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0635","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1039\/C8BM00466H","article-title":"Immunomodulatory vasoactive intestinal peptide amphiphile micelles","volume":"6","author":"Zhang","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0640","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.974411","article-title":"Trial watch: peptide-based anticancer vaccines","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0645","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0650","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1158\/1078-0432.CCR-15-0233","article-title":"Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival","volume":"21","author":"Reed","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0655","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-10-2614","article-title":"MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T cell responses against breast and ovarian cancer","volume":"17","author":"Morse","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0660","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0665","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0670","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0675","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/1744666X.2015.987663","article-title":"Dendritic cell-based vaccine research against cancer","volume":"11","author":"Mody","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0680","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nm1039","article-title":"Dendritic cell immunotherapy: mapping the way","volume":"10","author":"Figdor","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0685","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40259-015-0140-7","article-title":"Sipuleucel-T (Provenge\u00ae)-autopsy of an innovative paradigm change in cancer treatment: why a single-product biotech company failed to capitalize on its breakthrough invention","volume":"29","author":"Jaroslawski","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0690","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4161\/onci.21494","article-title":"Trial watch: dendritic cell-based interventions for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0695","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","article-title":"Survival with AGS-003, an autologous dendritic cell\u2013based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results","volume":"3","author":"Amin","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0700","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","article-title":"Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0705","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.2002.08.071","article-title":"Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group (SWOG-9035)","volume":"20","author":"Sondak","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0710","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","article-title":"Whole tumor antigen vaccines: where are we?","volume":"3","author":"Chiang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0715","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines: the promise and limitations in clinical trials","volume":"10","author":"Srivatsan","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0720","series-title":"Seminars in Immunology","first-page":"132","article-title":"Whole tumor antigen vaccines","author":"Chiang","year":"2010"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0725","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pbc.22319","article-title":"Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours","volume":"54","author":"Ardon","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028732","article-title":"Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses","volume":"6","author":"Chiang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0735","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biomaterials.2016.10.047","article-title":"Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine","volume":"113","author":"Shi","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0740","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13046-016-0444-6","article-title":"Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens","volume":"35","author":"Iranpour","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0745","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000359","article-title":"In situ regulation of DC subsets and T cells mediates tumor regression in mice","volume":"1","author":"Ali","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0750","first-page":"1569","article-title":"Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines, Cancer Immunology","volume":"57","author":"De Gruijl","year":"2008","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0755","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41467-018-03915-4","article-title":"A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0760","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor\u2014secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0765","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/mt.2011.269","article-title":"Phase I trial of \u201cbi-shRNAifurin\/GMCSF DNA\/autologous tumor cell\u201d vaccine (FANG) in advanced cancer","volume":"20","author":"Senzer","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0770","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.1506.abs","article-title":"Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases","volume":"94","author":"Berd","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0775","first-page":"114","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0780","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/imt.09.35","article-title":"Why current peptide-based cancer vaccines fail: lessons from the three Es","volume":"1","author":"Claesson","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0785","series-title":"Cancer Vaccines","first-page":"479","article-title":"The use of dendritic cells for peptide-based vaccination in cancer immunotherapy","author":"Salem","year":"2014"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0790","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrc.2015.3","article-title":"Biomaterials and emerging anticancer therapeutics: engineering the microenvironment","volume":"16","author":"Gu","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0795","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2012.09.033","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"64","author":"Brannon-Peppas","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0800","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cell.2015.03.037","article-title":"Immunoengineering: how nanotechnology can enhance cancer immunotherapy","volume":"161","author":"Goldberg","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0805","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: a review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Therapeut. Adv. Vaccin."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0810","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0815","first-page":"21","article-title":"Toxicity of some charged lipids used in liposome preparations","volume":"37","author":"Campbell","year":"1983","journal-title":"Cytobios"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0820","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2009.05.036","article-title":"Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties","volume":"139","author":"Zucker","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0825","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","article-title":"Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation","volume":"338","author":"Yang","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0830","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1016\/j.vaccine.2008.07.035","article-title":"Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity","volume":"26","author":"Hamdy","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0835","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0840","series-title":"Nanomedicine in Cancer","first-page":"197","article-title":"Preparation of drug-loaded polymeric nanoparticles","author":"Reis","year":"2017"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0845","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/S0006-3495(00)76549-0","article-title":"From liposomes to supported, planar bilayer structures on hydrophilic and hydrophobic surfaces: an atomic force microscopy study","volume":"79","author":"Jass","year":"2000","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0855","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/2008-2231-21-58","article-title":"Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel","volume":"21","author":"Manoochehri","year":"2013","journal-title":"DARU J. Pharmaceut. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0860","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2011.09.008","article-title":"Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals","volume":"420","author":"Qin","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0865","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biomaterials.2018.07.052","article-title":"Poly (propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines","volume":"182","author":"Qiu","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0870","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2015.03.029","article-title":"Feasibility of a subcutaneously administered block\/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model","volume":"206","author":"Cui","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0875","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2014.03.041","article-title":"Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses","volume":"191","author":"Keller","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0880","doi-asserted-by":"crossref","first-page":"18722","DOI":"10.1021\/acsami.6b06275","article-title":"Assembly and immunological processing of polyelectrolyte multilayers composed of antigens and adjuvants","volume":"8","author":"Chiu","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0885","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1021\/jacs.5b09974","article-title":"Emerging frontiers in drug delivery","volume":"138","author":"Tibbitt","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0890","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2013.03.010","article-title":"Immune system targeting by biodegradable nanoparticles for cancer vaccines","volume":"168","author":"Silva","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0895","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-10-3","article-title":"Improvement of different vaccine delivery systems for cancer therapy","volume":"10","author":"Bolhassani","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0900","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1038\/ncomms8556","article-title":"Injectable cryogel-based whole-cell cancer vaccines","volume":"6","author":"Bencherif","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0905","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nbt.3071","article-title":"Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy","volume":"33","author":"Kim","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0910","article-title":"Biomaterial-assisted targeted modulation of immune cells in cancer treatment","volume":"1","author":"Wang","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0915","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2230-973X.160844","article-title":"Mesoporous silica nanoparticles in target drug delivery system: a review","volume":"5","author":"Bharti","year":"2015","journal-title":"Int. J. Pharmaceut. Invest."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0920","article-title":"Injectable, tough alginate cryogels as cancer vaccines","volume":"1701469","author":"Shih","year":"2018","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0925","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/ten.teb.2007.0332","article-title":"Cell encapsulation in biodegradable hydrogels for tissue engineering applications","volume":"14","author":"Nicodemus","year":"2008","journal-title":"Tissue Eng. B Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0930","doi-asserted-by":"crossref","first-page":"1606036","DOI":"10.1002\/adma.201606036","article-title":"Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook","volume":"29","author":"Wang","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0935","doi-asserted-by":"crossref","first-page":"1703969","DOI":"10.1002\/adma.201703969","article-title":"Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity","volume":"29","author":"Kroll","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0940","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2004.09.003","article-title":"Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens","volume":"57","author":"Jiang","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0945","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1172\/JCI73316","article-title":"Emerging roles of lymphatic endothelium in regulating adaptive immunity","volume":"124","author":"Card","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0950","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1470-2045(13)70608-9","article-title":"Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review","volume":"15","author":"Lallas","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0955","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/acs.bioconjchem.7b00761","article-title":"Subcutaneous nanodisc vaccination with neoantigens for combination cancer immunotherapy","volume":"29","author":"Kuai","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0960","first-page":"e50984","article-title":"Intra-lymph node injection of biodegradable polymer particles","volume":"2","author":"Andorko","year":"2014","journal-title":"J. Visual. Exp."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0965","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1002\/eji.200535076","article-title":"Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens","volume":"35","author":"Johansen","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0970","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/eji.200425599","article-title":"Direct intralymphatic injection of peptide vaccines enhances immunogenicity","volume":"35","author":"Johansen","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0975","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.3748\/wjg.v20.i30.10383","article-title":"Hepatitis B vaccine by intradermal route in non responder patients: an update","volume":"20","author":"Filippelli","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.jconrel.2018.10.008_bb0980","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14760584.2014.883285","article-title":"Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature","volume":"13","author":"Herzog","year":"2014","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0985","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1080\/21645515.2015.1017694","article-title":"Best vaccination practice and medically attended injection site events following deltoid intramuscular injection","volume":"11","author":"Cook","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0990","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/ajkd.2000.19099","article-title":"A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients","volume":"36","author":"Charest","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jconrel.2018.10.008_bb0995","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1000","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/S0264-410X(00)00096-7","article-title":"Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9\u201311, 12\u201314 or 15\u201317 months of age\u2606","volume":"18","author":"Klinge","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1005","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/acsbiomaterials.8b00511","article-title":"Peptide amphiphile micelle vaccine size and charge influence the host antibody response","volume":"4","author":"Zhang","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1039\/C6BM00500D","article-title":"Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing","volume":"5","author":"Chang","year":"2017","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1020","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2014.10.006","article-title":"The immunophenotype of antigen presenting cells of the mononuclear phagocyte system in normal human liver\u2013A systematic review","volume":"62","author":"Strauss","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1035","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bpj.2010.06.016","article-title":"Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions","volume":"99","author":"Stylianopoulos","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1040","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/acsnano.5b02153","article-title":"Polyelectrolyte multilayers assembled entirely from immune signals on gold nanoparticle templates promote antigen-specific T cell response","volume":"9","author":"Zhang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1208\/s12248-014-9686-4","article-title":"Cationic liposomes loaded with a synthetic long peptide and poly (I: C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity","volume":"17","author":"Varypataki","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.12.024","article-title":"Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses","volume":"200","author":"Zeng","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2016.01.050","article-title":"Immune responses to vaccines delivered by encapsulation into and\/or adsorption onto cationic lipid-PLGA hybrid nanoparticles","volume":"225","author":"Liu","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biomaterials.2017.01.010","article-title":"Tailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines","volume":"122","author":"Zeng","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1065","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1039\/c3nr05559k","article-title":"Effect of polyethyleneglycol (PEG) chain length on the bio\u2013nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells","volume":"6","author":"Pozzi","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1078\/0171-9335-00363","article-title":"PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles","volume":"83","author":"Mishra","year":"2004","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061646","article-title":"Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice","volume":"8","author":"Kourtis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1080","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic nanoparticles for vaccines and immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.peptides.2016.11.011","article-title":"In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides","volume":"87","author":"Bolhassani","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1090","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2012-09-452078","article-title":"Targeting dendritic cells\u2014why bother?","volume":"121","author":"Kreutz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1126\/science.1136080","article-title":"Differential antigen processing by dendritic cell subsets in vivo","volume":"315","author":"Dudziak","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1120","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","article-title":"CD8+ but not CD8\u2212 dendritic cells cross-prime cytotoxic T cells in vivo","volume":"192","author":"Den Haan","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1125","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/acs.bioconjchem.7b00313","article-title":"Targeting CpG adjuvant to lymph node via dextran conjugate enhances antitumor immunotherapy","volume":"28","author":"Zhang","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.biomaterials.2016.05.008","article-title":"Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy","volume":"98","author":"Qian","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1135","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/anie.201508626","article-title":"Engineering polymer hydrogel nanoparticles for lymph node-targeted delivery","volume":"55","author":"De Koker","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1140","article-title":"Polyethylene glycol density and length affects nanoparticle uptake by cancer cells","volume":"1","author":"Cruje","year":"2014","journal-title":"J. Nanomed. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1145","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jconrel.2015.09.063","article-title":"Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy","volume":"219","author":"Leleux","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1150","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.6","article-title":"Targeting dendritic cells: a promising strategy to improve vaccine effectiveness","volume":"5","author":"Macri","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1160","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1016\/j.vaccine.2012.09.036","article-title":"A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles","volume":"30","author":"Raghuwanshi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1165","series-title":"Seminars in Immunology","first-page":"12","article-title":"Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines","author":"Tacken","year":"2011"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biomaterials.2014.10.053","article-title":"CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses","volume":"40","author":"Rosalia","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1175","first-page":"5231","article-title":"Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen","volume":"9","author":"Saluja","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1180","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2012-01-402370","article-title":"Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells","volume":"120","author":"Chatterjee","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development\u2013Progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1190","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9624","article-title":"A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy","volume":"7","author":"Yan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1195","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1096\/fj.12-224758","article-title":"A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells","volume":"27","author":"Sioud","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1200","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2012-09-452078","article-title":"Targeting dendritic cells: why bother?","volume":"12","author":"Kreutz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3920\/BM2016.0116","article-title":"Alleviation of enterotoxigenic Escherichia coli challenge by recombinant Lactobacillus plantarum expressing a FaeG-and DC-targeting peptide fusion protein","volume":"8","author":"Yang","year":"2017","journal-title":"Benefic. Microbes"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1210","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fimmu.2012.00406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"HogenEsch","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.007","article-title":"Immunomodulatory properties of the vaccine adjuvant alum","volume":"28","author":"Oleszycka","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1220","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.vaccine.2017.12.017","article-title":"A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses","volume":"36","author":"Rudra","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1225","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2017.09.017","article-title":"Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium","volume":"266","author":"de Groot","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2015.02.006","article-title":"Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation","volume":"203","author":"Rahimian","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2017.09.021","article-title":"Intradermal vaccination with hollow microneedles: a comparative study of various protein antigen and adjuvant encapsulated nanoparticles","volume":"266","author":"Du","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1245","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/acsbiomaterials.5b00375","article-title":"Modular vaccine design using carrier-free capsules assembled from polyionic immune signals","volume":"1","author":"Chiu","year":"2015","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biomaterials.2016.01.056","article-title":"Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses","volume":"86","author":"Molino","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1255","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/acsnano.7b09041","article-title":"Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination","volume":"12","author":"Yang","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1260","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1021\/acs.nanolett.7b03218","article-title":"Immunogenic cell death amplified by co-localized adjuvant delivery for cancer immunotherapy","volume":"17","author":"Fan","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1265","first-page":"29","article-title":"Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity","author":"Kroll","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1270","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2017.02.031","article-title":"Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination","volume":"251","author":"Mohsen","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1275","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1280","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1285","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tcb.2013.12.002","article-title":"Trafficking of endosomal Toll-like receptors","volume":"24","author":"Lee","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1295","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2249.2004.02433.x","article-title":"Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis","volume":"136","author":"Armstrong","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1208\/s12248-018-0233-6","article-title":"Vaccine adjuvant incorporation strategy dictates peptide amphiphile micelle immunostimulatory capacity","volume":"20","author":"Zhang","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1305","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.20.100301.064828","article-title":"Antigen presentation and T cell stimulation by dendritic cells","volume":"20","author":"Guermonprez","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1310","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fphys.2012.00138","article-title":"Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms","volume":"3","author":"Yang","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1315","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1016\/j.vaccine.2005.01.093","article-title":"Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition","volume":"23","author":"Daftarian","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1320","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1016\/j.bmc.2014.09.042","article-title":"Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant","volume":"22","author":"Azmi","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1325","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose","volume":"110","author":"De Titta","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1330","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/acs.bioconjchem.7b00697","article-title":"Environmentally triggerable retinoic acid-inducible gene i agonists using synthetic polymer overhangs","volume":"29","author":"Palmer","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1335","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1073\/pnas.1214994110","article-title":"Sortase-mediated modification of \u03b1DEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes","volume":"110","author":"Swee","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1340","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1021\/ml300482z","article-title":"Immune-stimulatory dinucleotide at the 5\u2032-end of oligodeoxynucleotides is critical for TLR9-mediated immune responses","volume":"4","author":"Putta","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1345","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/bc0200374","article-title":"Conjugation of ligands at the 5 \u2018-end of CpG DNA affects immunostimulatory activity","volume":"13","author":"Kandimalla","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/bc900425s","article-title":"Peptide conjugation at the 5\u2032-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity","volume":"21","author":"Putta","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1355","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/acs.molpharmaceut.7b00335","article-title":"Immunostimulatory properties of lipid modified cpg oligonucleotides","volume":"14","author":"Yu","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1360","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/jacs.7b12579","article-title":"Conjugation chemistry-dependent t-cell activation with spherical nucleic acids","volume":"140","author":"Skakuj","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1365","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.immuni.2009.09.018","article-title":"Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer","volume":"31","author":"Kang","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1370","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1021\/jm201071e","article-title":"Structure\u2013activity relationships in Toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides","volume":"54","author":"Agnihotri","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012550","article-title":"The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation","volume":"5","author":"Azuma","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1380","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/cbic.200900242","article-title":"Lipopeptides from Staphylococcus aureus as Tlr2 Ligands: prediction with mrna expression, chemical synthesis, and immunostimulatory activities","volume":"10","author":"Fujimoto","year":"2009","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1385","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1034\/j.1600-0463.2003.11107802.x","article-title":"Some interfaces of dendritic cell biology","volume":"111","author":"Steinman","year":"2003","journal-title":"APMIS"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1390","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1178331","article-title":"Development of monocytes, macrophages, and dendritic cells","volume":"327","author":"Geissmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1395","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.coi.2005.06.002","article-title":"Alarmins: chemotactic activators of immune responses","volume":"17","author":"Oppenheim","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1400","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1189\/jlb.0809546","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo","volume":"89","author":"Khajah","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1405","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nri1670","article-title":"Dendritic-cell trafficking to lymph nodes through lymphatic vessels","volume":"5","author":"Randolph","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1415","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1096\/fj.11-184556","article-title":"Antigen depot is not required for alum adjuvanticity","volume":"26","author":"Hutchison","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1420","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1425","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.181.6.3755","article-title":"Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome","volume":"181","author":"Kool","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1430","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1016\/j.vaccine.2013.05.107","article-title":"Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1435","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3329\/icpj.v4i8.24024","article-title":"Safety and mechanism of action of licensed vaccine adjuvants","volume":"4","author":"Rambe","year":"2015","journal-title":"Int. Curr. Pharm. J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1440","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1445","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1450","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/21645515.2015.1071455","article-title":"Safety and tolerability evaluation of the use of Montanide ISA\u2122 51 as vaccine adjuvant: a systematic review","volume":"12","author":"van Doorn","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1455","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.vaccine.2017.02.005","article-title":"Dynamics of APC recruitment at the site of injection following injection of vaccine adjuvants","volume":"35","author":"van Aalst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1460","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","article-title":"Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells","volume":"188","author":"Shirota","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1465","article-title":"Effects of aged garlic extract and FruArg on gene expression and signaling pathways in lipopolysaccharide-activated microglial cells","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1470","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/1521-4141(200106)31:6<1780::AID-IMMU1780>3.0.CO;2-I","article-title":"Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity","volume":"31","author":"Casares","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1475","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1480","first-page":"1","article-title":"Chemokine and chemotactic signals in dendritic cell migration","author":"Tiberio","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1485","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/bit.26532","article-title":"Precision-porous templated scaffolds of varying pore size drive dendritic cell activation","volume":"115","author":"Chen","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1490","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1021\/bm501166j","article-title":"In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice","volume":"15","author":"Liu","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1495","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nbt0102-64","article-title":"Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine","volume":"20","author":"Kumamoto","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1500","series-title":"Open pore biodegradable matrices formed with gas foaming","author":"Harris","year":"1998"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1505","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-13-0777","article-title":"Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants","volume":"74","author":"Ali","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1510","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nmat2357","article-title":"Infection-mimicking materials to program dendritic cells in situ","volume":"8","author":"Ali","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1515","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00392-011-0303-6","article-title":"Clinical experience with a novel subcutaneous implantable defibrillator system in a single center","volume":"100","author":"Abkenari","year":"2011","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1520","doi-asserted-by":"crossref","first-page":"19590","DOI":"10.1073\/pnas.1211516109","article-title":"Injectable preformed scaffolds with shape-memory properties","volume":"109","author":"Bencherif","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1525","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.actbio.2017.11.024","article-title":"Injectable nanocomposite cryogels for versatile protein drug delivery","volume":"65","author":"Koshy","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1530","first-page":"23","article-title":"Hyaluronic acid hydrogels for biomedical applications","author":"Burdick","year":"2011","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1535","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00006534-199909020-00018","article-title":"Transdermal photopolymerization of poly (ethylene oxide)-based injectable hydrogels for tissue-engineered cartilage","volume":"104","author":"Elisseeff","year":"1999","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1540","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpb.2007.02.025","article-title":"Thermoresponsive hydrogels in biomedical applications","volume":"68","author":"Klouda","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1545","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/polym3031215","article-title":"Thermoresponsive polymers for biomedical applications","volume":"3","author":"Ward","year":"2011","journal-title":"Polymer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1550","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1021\/bm060991u","article-title":"In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier","volume":"8","author":"Hyun","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1555","doi-asserted-by":"crossref","first-page":"20315","DOI":"10.1021\/acsami.8b04312","article-title":"Injectable hydrogels coencapsulating granulocyte-macrophage colony-stimulating factor and ovalbumin nanoparticles to enhance antigen uptake efficiency","volume":"10","author":"Sun","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1560","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.biomaterials.2016.01.026","article-title":"The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration","volume":"83","author":"Li","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1565","doi-asserted-by":"crossref","DOI":"10.1016\/j.joms.2016.06.077","article-title":"Development of mesoporous silica rod-based immunotherapies for head and neck squamous cell carcinoma","volume":"74","author":"Young","year":"2016","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1570","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.bioconjchem.7b00656","article-title":"Covalent conjugation of peptide antigen to mesoporous silica rods to enhance cellular responses","volume":"21","author":"Dellacherie","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1575","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/adma.201104763","article-title":"Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery","volume":"24","author":"Tang","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1580","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2016.e00225","article-title":"Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant Mycoplasma hyopneumoniae antigen vaccines","volume":"3","author":"Virginio","year":"2017","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1585","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/anie.201506179","article-title":"Stimulation of in vivo antitumor immunity with hollow mesoporous silica nanospheres","volume":"55","author":"Wang","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1590","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.antiviral.2017.07.009","article-title":"A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice","volume":"145","author":"Chen","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1595","doi-asserted-by":"crossref","DOI":"10.1038\/srep40312","article-title":"Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate","volume":"7","author":"Radtke","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1600","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3201\/eid2305.161630","article-title":"Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection","volume":"23","author":"Collins","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1605","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/intimm\/dxu055","article-title":"Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens","volume":"26","author":"Sheppard","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1610","article-title":"Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy","volume":"6","author":"He","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1615","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. 1","volume":"105","author":"Coley","year":"1893","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1620","first-page":"955","article-title":"Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity","volume":"72","author":"Tokunaga","year":"1984","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1625","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1630","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","article-title":"Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells","volume":"188","author":"Shirota","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1635","doi-asserted-by":"crossref","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","article-title":"Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1640","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/0008-5472.CAN-16-1873","article-title":"PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors","volume":"77","author":"Charlebois","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1645","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CJI.0000000000000145","article-title":"Synthetic poly (L-glutamic acid)-conjugated CpG exhibits antitumor efficacy with increased retention in tumor and draining lymph nodes after intratumoral injection in a mouse model of melanoma","volume":"40","author":"Ma","year":"2017","journal-title":"J. Immunotherapy"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1650","doi-asserted-by":"crossref","first-page":"9311","DOI":"10.1039\/C8NR01376D","article-title":"Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity","volume":"10","author":"An","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1655","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-12-3343","article-title":"Localized immunotherapy via liposome-anchored Anti-CD137+ IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity","volume":"73","author":"Kwong","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1660","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2326-6066.CIR-15-0112","article-title":"Engineering new approaches to cancer vaccines","volume":"3","author":"Mehta","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1665","first-page":"4102","article-title":"In-situ vaccination using sting agonists combined with immune-modulating antibodies to treat lymphoma","volume":"130","author":"Sallets","year":"2017","journal-title":"Am. Soc. Hematol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1670","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1675","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1021\/acsnano.7b00715","article-title":"Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer","volume":"11","author":"Xu","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1680","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1685","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1690","first-page":"1223","article-title":"Systemic therapy of metastatic melanoma","volume":"13","author":"Rauschenberg","year":"2015","journal-title":"JDDG"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1695","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann. Surg."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1700","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000007","article-title":"CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model","volume":"37","author":"Son","year":"2014","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1710","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrc.2017.83","article-title":"Engineering and physical sciences in oncology: challenges and opportunities","volume":"17","author":"Mitchell","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1715","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-12-3058","article-title":"Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment","volume":"73","author":"Le","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1720","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1016\/j.biomaterials.2011.03.067","article-title":"Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy","volume":"32","author":"Kwong","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1725","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2012.09.006","article-title":"Nanoparticles in cancer therapy and diagnosis","volume":"64","author":"Brigger","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1730","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/nat.2014.0509","article-title":"Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration","volume":"25","author":"Kim","year":"2015","journal-title":"Nucleic acid Therapeut."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1735","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.3390\/molecules22122167","article-title":"The use of liposomes and nanoparticles as drug delivery systems to improve cancer treatment in dogs and cats","volume":"22","author":"Zabielska-Koczyw\u0105s","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1740","series-title":"AACR","article-title":"Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration","author":"Naik","year":"2017"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1745","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1208\/s12248-014-9676-6","article-title":"Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer","volume":"17","author":"Makkouk","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1750","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.biomaterials.2016.02.001","article-title":"Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot","volume":"85","author":"Kwon","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1755","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biomaterials.2017.09.014","article-title":"DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy","volume":"146","author":"Yata","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1760","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1158\/1078-0432.CCR-12-1911","article-title":"Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice","volume":"18","author":"Fan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1765","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1002\/adfm.201502139","article-title":"Induction of potent antitumor immunity by sustained release of cationic antigen from a DNA-based hydrogel with adjuvant activity","volume":"25","author":"Umeki","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1770","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ijpharm.2016.11.048","article-title":"Improved sustained release of antigen from immunostimulatory DNA hydrogel by electrostatic interaction with chitosan","volume":"516","author":"Ishii-Mizuno","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1775","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2009.10.030","article-title":"Hydrogel-based drug delivery systems: comparison of drug diffusivity and release kinetics","volume":"142","author":"Brandl","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1780","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C1SM06513K","article-title":"Shear-thinning hydrogels for biomedical applications","volume":"8","author":"Guvendiren","year":"2012","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1785","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2015.12","article-title":"The design of reversible hydrogels to capture extracellular matrix dynamics","volume":"1","author":"Rosales","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1790","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1795","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-15-2657","article-title":"Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma","volume":"22","author":"B\u00f6hm","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1800","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1805","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1810","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/acs.nanolett.7b00021","article-title":"Mediating passive tumor accumulation through particle size, tumor type, and location","volume":"17","author":"Perry","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","article-title":"The effect of nanoparticle size, shape, and surface chemistry on biological systems","volume":"14","author":"Albanese","year":"2012","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1820","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1021\/acsnano.7b05876","article-title":"Nanoparticles for immune cytokine TRAIL-based cancer therapy","volume":"12","author":"Guimar\u00e3es","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1825","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2009.04.010","article-title":"Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels","volume":"138","author":"Mikhail","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1830","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1021\/nl302638g","article-title":"PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics","volume":"12","author":"Perry","year":"2012","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1835","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1840","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1845","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.biomaterials.2018.01.052","article-title":"From neutral to zwitterionic poly (\u03b1-amino acid) nonfouling surfaces: effects of helical conformation and anchoring orientation","volume":"178","author":"Zhang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1850","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1073\/pnas.1512465112","article-title":"Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1855","doi-asserted-by":"crossref","DOI":"10.1002\/admi.201400225","article-title":"Molecular design of antifouling polymer brushes using sequence-specific peptoids","volume":"2","author":"Lau","year":"2015","journal-title":"Adv. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1860","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1021\/acsbiomaterials.8b00300","article-title":"Instructive design of triblock peptide amphiphiles for structurally complex micelle fabrication","volume":"4","author":"Zhang","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1865","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201700617","article-title":"A coating-free nonfouling polymeric elastomer","volume":"29","author":"Hung","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1870","doi-asserted-by":"crossref","first-page":"11243","DOI":"10.1021\/nn503732m","article-title":"Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries","volume":"8","author":"Anselmo","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1875","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nnano.2007.70","article-title":"Shape effects of filaments versus spherical particles in flow and drug delivery","volume":"2","author":"Geng","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1880","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/nnm.13.191","article-title":"Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles","volume":"9","author":"Toy","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1885","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.1216893110","article-title":"Particle shape enhances specificity of antibody-displaying nanoparticles","volume":"110","author":"Barua","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1890","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1021\/nl204175t","article-title":"Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation","volume":"12","author":"Smith","year":"2012","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1895","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1021\/nn500299p","article-title":"Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency","volume":"8","author":"Sykes","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1900","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/bm5003009","article-title":"Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy","volume":"15","author":"Zhong","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1905","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1910","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.pharmthera.2013.10.006","article-title":"Targeting tumor\u2013stromal interactions in bone metastasis","volume":"141","author":"Esposito","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1915","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1021\/acsnano.5b01320","article-title":"Clearance pathways and tumor targeting of imaging nanoparticles","volume":"9","author":"Yu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1920","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/aadb68","article-title":"Aptamer-displaying peptide amphiphile micelles as a cell-targeted delivery vehicle of peptide cargoes","author":"Smith","year":"2018","journal-title":"Phys. Biol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1925","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/nl500618u","article-title":"Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery","volume":"14","author":"Fang","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1930","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1935","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/sj.leu.2404787","article-title":"Identification of T-cell epitopes for cancer immunotherapy","volume":"21","author":"Kessler","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1940","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1945","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erv.10.58","article-title":"Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1","volume":"9","author":"Cebon","year":"2010","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1950","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 vaccines: new prospects for breast cancer therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1955","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1021\/tx300066z","article-title":"Generation of DNA-damaging reactive oxygen species via the autoxidation of hydrogen sulfide under physiologically relevant conditions: chemistry relevant to both the genotoxic and cell signaling properties of H2S","volume":"25","author":"Hoffman","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1960","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/nat.2017.0703","article-title":"Activation of frataxin protein expression by antisense oligonucleotides targeting the mutant expanded repeat","volume":"28","author":"Li","year":"2018","journal-title":"Nucleic acid Therapeut."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1965","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1970","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1975","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12859-018-2207-1","article-title":"NextSV: a meta-caller for structural variants from low-coverage long-read sequencing data","volume":"19","author":"Fang","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1980","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1985","doi-asserted-by":"crossref","first-page":"18223","DOI":"10.1039\/C7NR06484E","article-title":"Nicking enzyme-controlled toehold regulation for DNA logic circuits","volume":"9","author":"Pan","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2018.10.008_bb1990","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.analchem.5b04645","article-title":"single cell chemical proteomics with membrane-permeable activity-based probe for identification of functional proteins in lysosome of tumors","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2018.10.008_bb1995","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3389\/fimmu.2018.01499","article-title":"Neoantigen vaccine delivery for personalized anticancer immunotherapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2000","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","article-title":"Metastasis: a question of life or death","volume":"6","author":"Mehlen","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.008_bb2005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nbt0209-129","article-title":"The cancer vaccine roller coaster","volume":"27","author":"Goldman","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1158\/0008-5472.CAN-16-1711","article-title":"Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors","volume":"77","author":"Mittapalli","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13287-015-0228-5","article-title":"Bioprocessing strategies for the large-scale production of human mesenchymal stem cells: a review","volume":"6","author":"Panchalingam","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jconrel.2018.10.008_bb2025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/blr.2015.9999","article-title":"FDA's expedited approval mechanisms for new drug products","volume":"34","author":"Kepplinger","year":"2015","journal-title":"Biotechnol. Law Rep."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2030","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1208\/s12248-016-9970-6","article-title":"Where are the nanodrugs? An industry perspective on development of drug products containing nanomaterials","volume":"18","author":"Havel","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2035","first-page":"742","article-title":"Progress in nanomedicine: approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharmacy Therapeut."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2040","series-title":"Dendritic Cell Activating Scaffold in Melanoma","author":"ClinicalTrials.Gov","year":"2018"},{"key":"10.1016\/j.jconrel.2018.10.008_bb2045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd2251","article-title":"Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers","volume":"6","author":"Trusheim","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2050","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s11095-013-1190-5","article-title":"PLGA\/liposome hybrid nanoparticles for short-chain ceramide delivery","volume":"31","author":"Zou","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0169-409X(95)00026-4","article-title":"The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres","volume":"16","author":"Gref","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.10.008_bb2060","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1002\/jps.21358","article-title":"Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development","volume":"97","author":"Drummond","year":"2008","journal-title":"J. Pharm. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918305790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918305790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:38:41Z","timestamp":1759160321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918305790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":407,"alternative-id":["S0168365918305790"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.10.008","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomaterials for vaccine-based cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}